Hepatitis C virus (HCV) NS3/4A protease inhibitors play an important role in several of the combination regimens that have revolutionized the treatment of this disease, offering patients an excellent chance for a complete cure. Starting from inhibitors incorporating oxime-based P*-shelf moieties, a collaborative effort between Abbott Laboratories and Enanta Pharmaceuticals generated ABT-450 (paritaprevir, a component of Technivie™ and Viekira Pak™), incorporating novel P*-phenanthridine and P3-amide capping groups and pharmacokinetically boosted by ritonavir. The discovery and development of ABT-450 enabled one of the first IFN-free combination therapies for HCV genotype 1 infection and contributed to the transformation of the treatment of this chronic and deadly disease.
CITATION STYLE
McDaniel, K. F., Ku, Y. Y., Sun, Y., Chen, H. J., Shanley, J., Middleton, T., … Kempf, D. (2019). The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir. In Topics in Medicinal Chemistry (Vol. 31, pp. 389–413). Springer. https://doi.org/10.1007/7355_2018_42
Mendeley helps you to discover research relevant for your work.